|Title||Do Statins Reduce the Health and Health Care Costs of Obesity?|
|Publication Type||Journal Article|
|Year of Publication||2015|
|Authors||Gaudette, É, Goldman, DP, Messali, A, Sood, N|
|Date Published||2015 Jul|
|Keywords||Aged, Computer Simulation, Cost-Benefit Analysis, Health Care Costs, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Life Expectancy, Markov chains, Models, Economic, Obesity, Quality-Adjusted Life Years|
CONTEXT: Obesity impacts both individual health and, given its high prevalence, total health care spending. However, as medical technology evolves, health outcomes for a number of obesity-related illnesses improve. This article examines whether medical innovation can mitigate the adverse health and spending associated with obesity, using statins as a case study. Because of the relationship between obesity and hypercholesterolaemia, statins play an important role in the medical management of obese individuals and the prevention of costly obesity-related sequelae.
METHODS: Using well-recognized estimates of the health impact of statins and the Future Elderly Model (FEM)-an established dynamic microsimulation model of the health of Americans aged over 50 years-we estimate the changes in life expectancy, functional status and health care costs of obesity due to the introduction and widespread use of statins.
RESULTS: Life expectancy gains of statins are estimated to be 5-6 % greater for obese individuals than for healthy-weight individuals, but most of these additional gains are associated with some level of disability. Considering both medical spending and the value of quality-adjusted life-years, statins do not significantly alter the costs of class 1 and 2 obesity (body mass index [BMI] ≥30 and ≥35 kg/m(2), respectively) and they increase the costs of class 3 obesity (BMI ≥40 kg/m(2)) by 1.2 %.
CONCLUSIONS: Although statins are very effective medications for lowering the risk of obesity-associated illnesses, they do not significantly reduce the costs of obesity.
|User Guide Notes|
|PubMed Central ID||PMC4490078|
|Grant List||P01AG033559 / AG / NIA NIH HHS / United States |
P01 AG033559 / AG / NIA NIH HHS / United States
R56 AG045135 / AG / NIA NIH HHS / United States
P30 AG043073 / AG / NIA NIH HHS / United States
P30 AG024968 / AG / NIA NIH HHS / United States
P30AG024968 / AG / NIA NIH HHS / United States